Primary high-grade calcitonin-negative neuroendocrine carcinoma of the thyroid: a very rare cancer
Endocrinology, Diabetes & Metabolism Case Reports · 17.04.2018 · 2018
DOI: 10.1530/edm-18-0036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, erschienen am 17.04.2018. Verfasst von Joseph A Chorny und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Colorado Permanente Medical Group, Denver, Colorado, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).
Abstract (Originalsprache)
Most medullary thyroid carcinomas (MTCs) are low grade and produce calcitonin. There are some calcitonin-negative MTCs that produce only calcitonin gene-related peptide (CGRP). Rarely, MTCs are negative for calcitonin and CGRP peptides, but contain their corresponding mRNAs. Primary thyroid neuroendocrine neoplasms other than MTCs are extremely rare. We describe a primary high-grade neuroendocrine carcinoma that was negative for CGRP and calcitonin at both the protein and mRNA levels. A 42-year-old woman presented with a rapidly enlarging thyroid mass replacing most of the left lobe and isthmus. A computed tomography-guided core-needle biopsy was performed. The tumor was composed of sheets of small-to-medium sized epithelial cells. The cells were immunoreactive for pancytokeratin, synaptophysin, CD56 and thyroid transcription factor-1, but negative for CK7, CK20, CD45, CD99, ERG, chromogranin A, thyroglobulin, calcitonin, CGRP and carcinoembryonic antigen. The Ki-67 proliferation index was ~90%. In situ hybridization was negative for calcitonin mRNA. The patient was initially diagnosed as having a small cell carcinoma. She was treated with cisplatin and etoposide (VP16), followed by radiation therapy. Given the excellent clinical course, the tumor was reviewed and reclassified as a high-grade neuroendocrine carcinoma (non-small-cell type). Heretofore, only a few other similar high-grade neuroendocrine tumors with negative markers of C-cell derivation have been reported. In our case, the patient is cancer free five years after diagnosis, but in the other cases, the outcome was poor. Learning points: There are neuroendocrine carcinomas of the thyroid that do not produce calcitonin or calcitonin gene-related peptide. This category of calcitonin-negative neuroendocrine carcinomas is heterogeneous, consisting of low- and high-grade tumors. The high-grade neuroendocrine carcinomas of the thyroid are rare and generally have a poor prognosis. They are divided into small cell and non-small cell or large cell types.
Autor:innen und Institutionen
- Department of Pathology, Colorado Permanente Medical Group, Denver, Colorado, USA.
- Department of Endocrinology and Metabolism, Colorado Permanente Medical Group, Denver, Colorado, USA.
- Department of Anatomic Pathology, Clinical University Hospital, Santiago de Compostela, Spain.
Zitieren
APA
Chorny, J. A., Orrego, J. J., & Cameselle-Teijeiro, J. M. (2018). Primary high-grade calcitonin-negative neuroendocrine carcinoma of the thyroid: a very rare cancer. Endocrinology, Diabetes & Metabolism Case Reports, 2018. https://doi.org/10.1530/edm-18-0036
Vancouver
Chorny JA, Orrego JJ, Cameselle-Teijeiro JM. Primary high-grade calcitonin-negative neuroendocrine carcinoma of the thyroid: a very rare cancer. Endocrinology, Diabetes & Metabolism Case Reports. 2018;2018. doi:10.1530/edm-18-0036
BibTeX
@article{Chorny2018,
author = {Chorny, Joseph A and Orrego, John J and Cameselle-Teijeiro, José Manuel},
title = {Primary high-grade calcitonin-negative neuroendocrine carcinoma of the thyroid: a very rare cancer},
journal = {Endocrinology, Diabetes & Metabolism Case Reports},
year = {2018},
volume = {2018},
doi = {10.1530/edm-18-0036}
}
EUVIMED